Vertaling van "innovation and provision of " (Nederlands → Frans) :

European Commission, High level group on innovation and provision of medicines, recommendations for action., 7 May 2002, G10 medicines report. [http ...]
European Commission, High level group on innovation and provision of medicines, recommendations for action. 7 May 2002, G10 medicines report. [http ...]

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

149026000094 SKS Modulair TA6V non cimentée (41X00924) (B&Co Hospital Innovations) 149026000103 SKS Monobloc mobile CoCr non cimentée (42x00927) (B&Co Hospital Innovations) 149026000112 SKS Monobloc rotatoire CoCr non cimentée (42x00929) (B&Co Hospital Innovations) 149026000121 Embase tibiale Ceragyr (650x) (Belgafix) 149026000137 Embase tibiale Hermes (519x) (Belgafix) 149026000191 LCS Universal Tibial Tray Porous (17790x050) (DePuy - J&J) 149026000216 MBT Porous Tibial Tray Keeled (1294 34 1xx) (DePuy - J&J) 149026000286 T.A.C. K'.
149026000112 SKS Monobloc rotatoire CoCr non cimentée (42x00929) (B&Co Hospital Innovations) 149026000121 Embase tibiale Ceragyr (650x) (Belgafix) 149026000137 Embase tibiale Hermes (519x) (Belgafix) 149026000191 LCS Universal Tibial Tray Porous (17790x050) (DePuy - J&J) 149026000216 MBT Porous Tibial Tray Keeled (1294 34 1xx) (DePuy - J&J) 149026000286 T.A.C. K'.

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

The provision of scientific advice at the level of the EMEA has been a particular success in recent years.
The provision of scientific advice at the level of the EMEA has been a particular success in recent years.

Verminderingen “research, development and innovation” Om te kunnen genieten van het systeem van vermindering dat van toepassing is in het geval van investeringen op het vlak van onderzoek, ontwikkeling en innovatie, moeten de farmaceutische firma's die de heffingen op de omzet van vergoedbare farmaceutische specialiteiten hebben betaald aan het RIZIV, een aanvraag indienen bij de Dienst voor geneeskundige verzorging van het RIZIV. De investeringen die in aanmerking worden genomen voor de toepassing van deze maatregel zijn de investeringen die in België dan wel in het buitenland worden gedaan, op voorwaarde dat de firma die de aanvraag heeft ingediend een stabiele vestiging in België heeft en dat het personeel van deze stabiele vestiging de opvolging en controle van de activiteiten van onderzoek, ontwikkeling of innovatie waarborgt die het recht openen op de vermindering.
Diminutions « recherche, développement et innovation » Pour bénéficier du régime de réduction applicable en cas d'investissements en matière de recherche, de développement et d'innovation, les firmes pharmaceutiques qui ont payé leurs cotisations sur le chiffre d'affaires des spécialités pharmaceutiques remboursables à l'INAMI doivent introduire une demande auprès du Service des soins de santé de l'INAMI. Les investissements qui entrent en ligne de compte pour l'application de cette mesure sont aussi bien les investissements réalisés en Belgique que les investissements réalisés à l'étranger, dès lors que la firme qui a introduit la demande a un établissement stable en Belgique et que c'est le personnel de cet établissement stable qui assure le suivi et le contrôle des activités de recherche, de développement ou d'innovation qui donnent droit à la réduction.

149001000041 Hermes (1228 -> 1231, 1302) (Belgafix) 149001000145 OPTETRAK UNI (250.01.xx) (ORTHO-TEAM) 149005000067 SKS condyle standard non cimenté (42x001x2) (B&Co Hospital Innovations) 149005000076 CERAGYR sans ciment (661x, 611x (Belgafix) 149005000094 Hermes sans ciment (561x, 551x (Belgafix) 149005000295 T.A.C. K'.
149005000076 CERAGYR sans ciment (661x, 611x (Belgafix) 149005000094 Hermes sans ciment (561x, 551x (Belgafix) 149005000295 T.A.C. K'.

remettent leur pratique en question sont ouverts à l’évaluation, à l’innovation, à la formation continue sont impliqués dans la promotion de la profession participent à l’organisation collective de la première ligne de soins.
kritisch reflecteren openstaan voor evaluatie, innovatie, navorming betrokken zijn bij de promotie van het beroep deelnemen aan de collectieve organisatie van de eerste lijn.

Offrir et maintenir des infrastructures comme du personnel (par exemple par la formation et l’enseignement), des structures et de l’équipement Être innovant Répondre aux besoins émergents Rester financé durablement par des recettes collectives.
een infrastructuur, zoals een personeelsbestand, ter beschikking te stellen en te behouden (bijv. door opleiding en training, voorzieningen en uitrusting) innoverend te zijn te reageren op nieuw ontstane noden duurzaam gefinancierd te blijven door collectieve ontvangsten.

La durabilité : dans quelle mesure le système est capable : d’offrir et maintenir une infrastructure comme du personnel (p.ex. par la formation et l’éducation), des structures et de l’équipement d’être innovant de répondre aux besoins émergents ?
Duurzaamheid: in welke mate laat het systeem toe om: infrastructuur ter beschikking te stellen en te behouden zoals personeel (bijv. via opleiding en training), voorzieningen en uitrusting innoverend te zijn een antwoord te vinden op bestaande noden?